Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 762 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New targeted treatments raise the bar in immunotherapy-resistant melanoma October 27, 2026 Why Have Thyroid Cancer Diagnoses Spiked for US Women? September 28, 2021 Man Becomes Nervous About How Cop Acts During Ticket, Then He... June 6, 2019 Reunión anual de la American Society of Clinical Oncology de 2022:... June 4, 2022 Load more HOT NEWS FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... Vaping Pods Produce High Nicotine Levels in Young Users Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence... Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced...
